

- **Name:** Inkeun Park
  - **Current Position & Affiliation:** Clinical Associate Professor, Asan Medical Center
  - **Country:** Korea
- 

• **Educational Background:**

- 1998. 3 – 2004.2 M.D. Kyunghee University College of Medicine, Seoul, Korea
- 2007. 3 – 2009.2 MSc, Postgraduate School, University of Ulsan College of Medicine, Seoul, Korea
- 2013. 2 – 2017.2 Ph.D., Postgraduate School, University of Ulsan College of Medicine, Seoul, Korea

• **Professional Experience:**

- 2014.3 – 2020.8 Assistant Professor, Medical Oncology, Gachon University Gil Medical Center, Incheon, Korea
- 2020.9 – 2022.2 Associate Professor, Medical Oncology, Gachon University Gil Medical Center, Incheon, Korea
- 2022.3- Clinical Associate Professor, Medical Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

• **Professional Organizations:**

- Member, Korean Medical Association
- Member, Korean Association of Internal Medicine
- Member, Korean Society of Medical Oncology
- Member, Korean Cancer Association
- Member, Korean Cancer Study Group
- Special Member, Korean Urological Oncology Society

• **Main Scientific Publications:**

1. Park I, Suh J, Lim B, Song C, You D, Jeong IG, Hong JH, Ahn H, Cho YM, Lee JL, Hong B. Effectiveness of adjuvant chemotherapy in variant histology upper tract urothelial carcinoma following radical nephroureterectomy: stabilized inverse probability treatment weighting analysis of single center experience. Clin Genitourin Cancer. 2024;22:102069
2. Pak C, YooS, Lee JL, Yun T, Park I. Current status and future direction in the treatment of advanced adrenocortical carcinoma. Curr Oncol Rep. 2024;26:307-317
3. Park YG, Park I, Kim Y, Lee HS, Lee W, Yoon S, Lee JL. Outcomes of systemic treatment according to germline mutational status in patients with metastatic pheochromocytoma and paraganglioma. Clin Genitourin Cancer. 2024;22:413-419

4. Kim MH, Lee EJ, Kim SJ, Jung YJ, Park WJ, Park I. Macrophage inhibitory cytokine-1 aggravates diet-induced gallstone formation via increased ABCG5/ABCG8 expression. PLoS One 2023;18(6):e0287146
5. Park JH, Park I, Kim IH, Hur JY, Hwang I, Kim C, Kim HJ, Maeng CH, Park K, Lee MY, Lee HJ, Jung JY, Keam B, Park SH, Lee JL. Prognostic model in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitors after platinum failure. Curr Probl Cancer. 2022;46:100848
6. Seo JY, Ahn JY, Keam B, Kim M, Yoon S, Lee JL, Park K, Park I. Genotypic and phenotypic characteristics of hereditary leiomyomatosis and renal cell cancer syndrome in Korean patients. Ann Lab Med. 2021;41:207-213
7. Park I, Lee JL. Systemic treatment for advanced urothelial cancer: an update on recent clinical trials and current treatment options. Korean J Intern Med 2020;35:834-853
8. Park I, Kim BS, Lim HY, Kim HJ, Lee HJ, Choi YJ, Park KH, Lee KH, Yoon S, Hong B, Hong JH, Ahn H, Lee JL: Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin-unfit patients with advanced urothelial carcinoma: a randomised phase II study (COACH, KCSG GU 10-16). Eur J Cancer 2020;127:183-190
9. Park JH, Yeo JH, Kim YS, Ahn HK, Sym S, Shin D, Hwang I, Park I, Kim JH. Portal vein stent for symptomatic malignant portal vein stenosis: a single-center experience. Curr Probl Cancer 2020;44:100476
10. Lee IH, Kang BW, Kim JG, Bae WK, Ki MS, Park I, Jo JC, Kim JY, Koh SA, Lee KH, Cho YY, Ryoo HM, Kwak SG, Lee JL, Lee SA. Comparison of three risk stratification models for non-clear cell renal cell carcinoma patients treated with temsirolimus as first-line therapy. Korea J Intern Med 2020;35:185-193
11. Park I, Shim YS, Go H, Hong BS, Lee JL. Long-term response of metastatic hereditary leiomyomatosis and renal cell carcinoma syndrome associated renal cell carcinoma to bevacizumab plus erlotinib after temsirolimus and axitinib treatment failures. BMC Urol 2019;19:51
12. Park I, Lee HJ, Bae WK, Yoon S, Lee JL: A multicenter, prospective phase II trial of gemcitabine plus axitinib in patients with renal cell carcinoma with a predominant sarcomatoid component. Invest New Drugs 2019;37:1239-1246

13. Kim EY, Park I, Kim YS, Ahn HK, Lee HY, Kim JH. Unusual radiologic manifestation of pseudoprogression in pulmonary metastases after durvalumab treatment in metastatic bladder urothelial cancer. Thorac Cancer 2019;10:1016-1018
14. Choi Y, Keam B, Kim M, Yoon S, Kim D, Choi YJ, Seo JY, Park I, Lee JL: Bevacizumab plus erlotinib combination therapy for advanced hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinoma: A multicenter retrospective analysis in Korean patients. Cancer Res Treat 2019;51:1549-1556